SGMOQ · Sangamo Therapeutics, Inc · Debt
$0.15
+0.00 (+1.51%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of significant losses, negative cash flows from operations, negative working capital, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued.”View the 10-Q filed May 14, 2026
Market Cap
$58.00M
Shares
414.29M
Volume · Oct 2
1.6M
Avg daily vol (3M)
2.74M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent operating lease liabilities | 2026-03-31 | USD 19,332,000 | 10-Q filed 2026-05-14 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.